Rhabdomyosarcoma of the corpus uteri

Rhabdomyosarcoma of the corpus uteri is an extremely rare malignant tumor arising from the body (corpus) of the uterus, composed of cells that show skeletal muscle differentiation. This aggressive soft tissue sarcoma can occur in the myometrium or endometrium and belongs to the broader category of uterine sarcomas. It may present as embryonal rhabdomyosarcoma (including the botryoid variant, also known as sarcoma botryoides) or other rhabdomyosarcoma subtypes. While rhabdomyosarcoma more commonly affects children in other body sites, uterine corpus involvement is predominantly seen in adult women, though rare cases in younger patients have been reported. Key symptoms include abnormal uterine bleeding, pelvic pain, a rapidly enlarging uterine mass, and sometimes a polypoid mass protruding through the cervix. Patients may also experience pressure symptoms on adjacent pelvic organs. Diagnosis is typically made through histopathological examination of biopsy or surgical specimens, with immunohistochemical staining for skeletal muscle markers such as desmin, myogenin, and MyoD1. The tumor can be locally aggressive and has the potential for distant metastasis, including to the lungs, liver, and lymph nodes. Treatment generally involves a multimodal approach including surgical resection (often hysterectomy with bilateral salpingo-oophorectomy), chemotherapy (commonly vincristine, actinomycin D, and cyclophosphamide-based regimens), and in some cases radiation therapy. Due to the extreme rarity of this tumor, treatment protocols are often adapted from rhabdomyosarcoma guidelines used in more common anatomical sites. Prognosis varies depending on stage at diagnosis, histological subtype, and response to treatment, but outcomes for uterine rhabdomyosarcoma are generally guarded given its aggressive nature.

Common questions about Rhabdomyosarcoma of the corpus uteri